The Medical Imaging & Technology Alliance (MITA) – the leading trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices – applauds the Food and Drug Administration’s (FDA) approval under the traditional pathway of Leqembi (lecanemab) for the treatment of people with mild cognitive impairment or mild dementia.
Click here to read the full article.